Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target
Ascendiant Capital maintained their Buy rating on Aytu BioPharma's stock with a price target of $15.00.The price target implies an upside of 581.8% from the Sep 29 close of $2.20.Key takeaways from the analyst noteStrong Financial Performance: Aytu BioPharma recently reported fiscal Q4 results that…